文献速递前列腺癌

IMU-935(新型RORγ/RORγt反向激动剂)单药治疗进展性转移性去势抵抗性前列腺癌的开放标签1期剂量探索研究

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-03-11

主要目的是采用贝叶斯最优区间设计确定推荐2期剂量。结果显示IMU-935耐受良好,未报告剂量限制性毒性(DLT)或任何≥3级不良事件(AE),但整体抗肿瘤活性不显著,仅一名错配修复缺陷(MMRd)患者出现PSA≥50%下降和影像学稳定疾病>6个月。

要点

  • IMU-935在mCRPC患者中耐受良好,未观察到DLT或≥3级AE。
  • 整体抗肿瘤活性有限,中位PSA进展时间8周,中位影像学无进展生存11周。
  • 仅一名MMRd患者出现PSA应答和影像学稳定疾病>6个月。

核心结论

  • IMU-935耐受良好,未报告DLT,但在未经分子筛选的mCRPC队列中未观察到稳健的抗肿瘤活性。

研究设计与样本

  • 主要目标为采用贝叶斯最优区间设计确定推荐2期剂量。

主要发现

  • 未报告DLT或任何≥3级AE。
  • 最常见治疗相关AE为1级恶心(n=4;22%)和1级呕吐(n=3;17%)。
  • 唯一观察到的2级治疗相关AE为贫血(n=2;11%)和胃食管反流病(n=1;6%)。
  • 6例(33%)患者循环肿瘤细胞(CTC)水平从≥5降至<5个/7.5 ml。
  • 一名MMRd患者出现PSA≥50%下降和影像学稳定疾病>6个月。

关键数值与推荐

  • 剂量水平:150 mg、300 mg或450 mg每日两次。
  • CTC应答:6例(33%)患者CTC从≥5降至<5个/7.5 ml。
  • PSA应答:仅1例MMRd患者PSA下降≥50%。
  • 中位PSA进展时间8周(范围2-36周),中位影像学无进展生存11周(范围3.4-36周)。

临床怎么用

  • IMU-935单药在未经分子筛选的mCRPC中抗肿瘤活性有限,不支持进一步在该人群中进行单药开发。
  • MMRd患者中观察到的PSA应答提示需在分子筛选人群(如MMRd)中进一步评估。

局限性

  • 队列未经分子筛选,MMRd亚组仅1例,无法得出亚组结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Retinoic acid receptor-related orphan receptor gamma (RORγ) is frequently overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and, together with retinoic acid-related orphan receptor gamma t (RORγt), can increase androgen receptor (AR) signalling and promote a proinflammatory tumour microenvironment. METHODS: In this phase 1 dose-finding study (NCT05124795), men with mCRPC received the oral RORγ/RORγt inverse agonist IMU-935 across three dose levels (150 mg, 300 mg, or 450 mg twice daily). The primary objective was to determine the recommended phase 2 dose according to a Bayesian optimal interval design. Key secondary endpoints included evaluation of pharmacokinetics and pharmacodynamics, as well as antitumour activity in terms of prostate-specific antigen (PSA), circulating tumour cells (CTCs), and responses according to Response Evaluation Criteria in Solid Tumours. KEY FINDINGS AND LIMITATIONS: Eighteen men received IMU-935. No dose-limiting toxicities (DLTs) or any grade (G) ≥3 adverse events (AEs) were reported. The most common treatment-related AEs (TRAEs) were G1 nausea (n = 4; 22%) and G1 vomiting (n = 3; 17%). The only G2 TRAEs observed were anaemia (n = 2; 11%) and gastroesophageal reflux disease (n = 1; 6%). Overall, six men (33%) had a decrease in CTC level from ≥5 to <5 cells/7.5 ml, while one participant whose tumour had mismatch repair deficiency (MMRd) experienced a ≥50% decline in PSA and radiologically stable disease for >6 mo. The median time to PSA progression was 8 wk (range 2-36 wk), and median radiological progression-free survival was 11 wk (range 3.4-36 wk). CONCLUSIONS AND CLINICAL IMPLICATIONS: IMU-935 was well tolerated with no DLTs. One participant with MMRd mCRPC experienced a PSA response. Overall, however, robust antitumour activity was not observed in this molecularly unselected cohort.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Grochot R, Guo C, Carreira S, et al. An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41820163. doi:10.1016/j.euo.2026.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。